glp-1 kidney disease news Real-World Evidence for Receptor Agonists Across the CKD Spectrum – AJKD Blog A true breakthrough': The eye-opening

Read the guide Medicare basics A plain-English breakdown of what each Medicare part covers, what it costs, and how they fit together for Washington State beneficiaries

The SURMOUNT trials demonstrated up to 22.5% mean weight loss at the highest dose

A large retrospective cohort study from Weill Cornell Medical College - examining 255 patients (92% women, mean age 64) with DXA scans before and after starting semaglutide or tirzepatide - found that GLP-1 receptor agonist use was associated with greater annualized total hip bone loss in patients without diabetes, while patients with diabetes showed bone loss more comparable to non-users

Semaglutide is known to reduce inflammation, improve metabolic health, and decrease visceral fat around the abdomen and organs, all factors linked to driving aging, particularly in people living with HIV

Super insightful post

Action of the diabetogenic drug streptozotocin on glycolytic and glycogenolytic metabolism in adult rat brain cortex and hippocampus